Austar Lifesciences Limited AULSF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 1.77% | -12.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 1.77% | -12.29% | |||
| Cost of Revenue | 1.77% | -13.15% | |||
| Gross Profit | 1.77% | -8.26% | |||
| SG&A Expenses | 1.77% | 11.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -1.77% | -232.99% | |||
| Total Operating Expenses | 1.77% | -12.37% | |||
| Operating Income | 1.77% | -8.94% | |||
| Income Before Tax | 1.77% | 1.43% | |||
| Income Tax Expenses | 1.78% | 5.32% | |||
| Earnings from Continuing Operations | 1.78% | -2.16% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -1.75% | 12.04% | |||
| Net Income | 1.77% | -1.63% | |||
| EBIT | 1.77% | -8.94% | |||
| EBITDA | 1.77% | -4.66% | |||
| EPS Basic | 0.00% | 0.00% | |||
| Normalized Basic EPS | 0.00% | 0.00% | |||
| EPS Diluted | 0.00% | 9.09% | |||
| Normalized Diluted EPS | 0.00% | 0.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||